Search This Blog

Wednesday, September 2, 2026

United Therapeutics gets FDA acceptance of sNDA for nebulized Tyvaso in idiopathic pulmonary fibrosis

 


  • FDA review of the nebulized Tyvaso sNDA for idiopathic pulmonary fibrosis expected to conclude by late April 2027.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)